centrifuges and growth factors
DESCRIPTION
CENTRIFUGES AND GROWTH FACTORS. Method: 6 samples of blood; Centrifuge (Silfradent protocol); Histomorphometrical analysis of growth factors: TGF- 1 e VEGF-A in Buffy Coat : 1) Buffy Coat, 2) Red-buffy coat Interface e 3 ) Red Blood Cells 1, 2, 3; - PowerPoint PPT PresentationTRANSCRIPT
CENTRIFUGES AND GROWTH FACTORS
Method:
- 6 samples of blood;
- Centrifuge (Silfradent protocol);
- Histomorphometrical analysis of growth factors: TGF-1 e VEGF-A in Buffy Coat:
1) Buffy Coat, 2) Red-buffy coat Interface e 3) Red Blood Cells 1, 2, 3;
- Quantitative analysis of TGF-1 e VEGF-A in blood serum;
- Histomorphometrical analysis of CD34+ cells in Red-Buffy Coat Interface.
BUFFY COAT
SERUM
RED BLOOD CELLS
Buffy Coat
Red Blood 1
Red Blood 2
Red Blood 3
MEDIFUGE- SILFRADENT
CONTROL CENTRIFUGE
Red- Buffy Coat Interface
VEGF-A serum
0
50
100
150
200
250
300
350
400
450
500
CONTROL CENTRIFUGE MEDIFUGE
pg
/ml
*
* P < 0,05 vs control centrifuge
VEGF-A serum concentration is lower in the samples treated with Medifuge-Silfradent compared with control centrifuge.
VEGF-A expression
The histomorphometrical analysis showed a greater expression of VEGF-A in the samples treated with Medifuge-Silfradent compared with control centrifuge.
* P < 0,05 vs control centrifuge
05
10152025303540
BUFFY COAT RED - BUFFYCOAT
INTERFACE
RED BLOOD1
RED BLOOD2
RED BLOOD3
IOD
CONTROL CENTRIFUGE MEDIFUGE
*
*
**
*
VEGF-A Buffy Coat
COAGULO
0
5
10
15
20
25
30
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P < 0,05 vs control centrifuge
Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth
factor in the Buffy Coat of samples treated with Medifuge-Silfradent compared with
control centrifuge.
MEDIFUGE
CONTROL
VEGF-A
Red – Buffy Coat Interface
0
5
10
15
20
25
30
35
40
CONTROL CENTRIFUGE MEDIFUGE
IOD
* P< 0,05 vs control centrifuge
*
Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth
factor in the Buffy Coat of samples treated with Medifuge-Silfradent compared with
control centrifuge.
MEDIFUGE
CONTROL
0
5
10
15
20
25
30
CONTROL CENTRIFUGE MEDIFUGE
IOD
* P< 0,05 vs control centrifuge
*
VEGF-A
Red Blood 1
Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Red Blood 1 of samples treated
with Medifuge-Silfradent compared with control centrifuge.
MEDIFUGE
CONTROL
VEGF-A
Red Blood 2
0
5
10
15
20
25
30
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P< 0,05 vs control centrifuge
Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Red Blood 2 of samples treated
with Medifuge-Silfradent compared with control centrifuge.
MEDIFUGE
CONTROL
VEGF-A
Red Blood 3
2424,5
2525,5
2626,5
2727,5
2828,5
2929,5
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P< 0,05 vs control centrifuge
Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Red Blood 3 of samples treated
with Medifuge-Silfradent with control centrifuge.
MEDIFUGE
CONTROL
TGF-β1
Serum
0
5
10
15
20
25
CONTROL CENTRIFUGE MEDIFUGE
ng
/ml
*
* P< 0,05 vs control centrifuge
TGF-β1 serum concentration is lower in samples treated with Medifuge-Silfradent compared with control centrifuge.
05
1015202530354045
BUFFY COAT RED- BUFFYCOAT
INTERFACE
RED BLOOD1
RED BLOOD2
RED BLOOD3
IOD
CONTROL CENTRIFUGE MEDIFUGE
*
*
**
*
* P < 0,05 vs control centrifuge
TGF-β1
expression
The histomorphometrical analysis showed a greater expression of TGF-β1 in samples treated with Medifuge-Silfradent compared with control centrifuge.
TGF-β1 Buffy Coat
0
5
10
15
20
25
30
CONTROL CENTRIFUGE MEDIFUGE
IOD
* P < 0,05 vs control centrifuge
*
Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this
growth factor in the Buffy Coat of samples treated with Medifuge-Silfradent compared
with control centrifuge.
MEDIFUGE
CONTROL
TGF-β1
Red – Buffy Coat Interface
Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this growth factor in the Red-Buffy Coat of
samples treated with Medifuge-Silfradent compared with control centrifuge.
0
5
10
15
20
25
30
35
40
45
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P < 0,05 vs control centrifuge
MEDIFUGE
CONTROL
TGF-β1
Red Blood 1
Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this
growth factor in the Red Blood 1 of samples treated with Medifuge-Silfradent compared
with control centrifuge.
0
5
10
15
20
25
30
35
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P < 0,05 vs control centrifuge
MEDIFUGE
CONTROL
TGF-β1
Red Blood 2
Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this
growth factor in the Red Blood 2 of samples treated with Medifuge-Silfradent compared
with control centrifuge.
0
5
10
15
20
25
30
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P < 0,05 vs control centrifuge
MEDIFUGE
CONTROL
TGF-β1
Red Blood 3
Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this
growth factor in the Red Blood 3 of samples treated with Medifuge-Silfradent compared
with control centrifuge.
0
5
10
15
20
25
30
35
CONTROL CENTRIFUGE MEDIFUGE
IOD
*
* P < 0,05 vs control centrifuge
MEDIFUGE
CONTROL
VEGF-A and TGF-β1 results
- The histomorphometric analysis (IOD) of blood growth factors TGF-1 and VEGF-A showed a greater expression of these growth factors in the samples treated with Medifuge-Silfradent compared with control centrifuge.
- Enzymatic analysis of VEGF-A e TGF-1 has confirmed our previous results showing a significant difference of both growth factors serum concentration: in particular, we found a lower serum concentration of both growth factors in the samples treated with Medifuge-Silfradent compared with control centrifuge.
Bar 10 μm
CD 34 Stem cells
Red- Buffy Coat Interface
- The immunohistochemical analysis of the Red-Buffy Coat Interface showed a greater number of white cells in samples treated with Medifuge-Silfradent centrifuge with control centrifuge, as suggest by our previous analysis.
- The immunohistochemical analysis of cells CD34+ expressed in the Red-Buffy Coat Interface showed a number of cells CD34+ four time greater in the samples trated with Medifuge-Silfradent centrifuge compared with control centrifuge.
MEDIFUGE
CONTROL